The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Radiation Therapy and Tamoxifen: Concurrent or Sequential? That Is the Question
Abstract
Randomized controlled trials have had an important impact on the treatment of women with early breast cancer. Many women routinely receive breast-conserving surgery plus radiation therapy, adjuvant chemotherapy, or hormonal therapy based on the results of randomized trials. However, despite the extensive use of combinations of chemotherapy, hormonal therapy, and radiation therapy, the optimal sequencing of these different adjuvant treatments for patients with early breast cancer remains unclear. Unfortunately, there have been few randomized trials addressing this important issue. In a randomized trial by Recht et al, 1 the optimal sequencing of radiation and chemotherapy in patients treated with breast-conserving surgery was evaluated. Of 244 patients, 122 were allocated to receive radiation therapy before anthracycline-based chemotherapy and 122 were allocated to receive radiation therapy after the same chemotherapy. The median length of follow-up was 58 months. Although the study was relatively small by today’s standards, there was a trend for an increased risk of distant recurrence for patients treated with radiation therapy first (36% v 25%; hazard ratio [HR], 1.62; 95% CI, 1.01 to 2.62;P .05). As a result, breast irradiation is now usually given after anthracycline-based chemotherapy. In early 1990s, investigators from the North American Breast Intergroup conducted a randomized trial in postmenopausal women with node-positive, hormone receptor–positive breast cancer, which compared tamoxifen, administered concurrently with cyclophosphamide, doxorubicin, and fluorouracil (n 550) with tamoxifen given after the completion of the same chemotherapy (n 566). 2 This was an important clinical question because there was some concern that the cytostatic effect of concurrent tamoxifen might interfere with the cytotoxic effects of chemotherapy on cancer cells. Preclinical data had demonstrated that human breast tumor cells in culture pretreated with tamoxifen were protected from the cytotoxicity of chemotherapy. 3 This concern was not shared by all investigators; several cooperative groups recommended the concurrent use of chemotherapy and tamoxifen in trials evaluating these agents. Furthermore, it had already been observed that combined chemotherapy and tamoxifen increased the risk of thromboembolic complications in patients. 4 With a median follow-up of 8.5 years, the results of the Intergroup study were presented at the 2000 American Society of Clinical Oncology Annual Meeting. The 8-year disease-free survival estimates were 67% for patients treated with sequential chemotherapy and tamoxifen compared with 62% for patients treated with concurrent chemotherapy and tamoxifen (P .05). 2 This study led to important
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hughes, K. S., Schnaper, L. A., Berry, D., Cirrincione, C., McCormick, B., Shank, B., Wheeler, J., Champion, L. A., Smith, T. J., Smith, B. L., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040587 · Cited by 1,078
Bartelink, H., Horiot, J.-C., Poortmans, P., Struikmans, H., Van den Bogaert, W., Barillot, I., Fourquet, A., Borger, J., Jager, J., Hoogenraad, W., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010874 · Cited by 941
Fisher, B., Bryant, J., Dignam, J. J., Wickerham, D. L., Mamounas, E. P., Fisher, E. R., Margolese, R. G., Nesbitt, L., Paik, S., Pisansky, T. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.101 · Cited by 667
Fyles, A. W., McCready, D. R., Manchul, L. A., Trudeau, M. E., Merante, P., Pintilie, M., Weir, L. M., & Olivotto, I. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040595 · Cited by 651
Recht, A., Come, S. E., Henderson, I. C., Gelman, R. S., Silver, B., Hayes, D. F., Shulman, L. N., & Harris, J. R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605233342102 · Cited by 436
Vinh-Hung, V., & Verschraegen, C. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh013 · Cited by 365
Radiotherapy-Related Lung Fibrosis Enhanced by Tamoxifen
Bentzen, S. M., Skoczylas, J. Z., Overgaard, M., & Overgaard, J. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.13.918 · Cited by 281
Limited-Field Radiation Therapy in the Management of Early-Stage Breast Cancer
Vicini, F. A., Kestin, L., Chen, P., Benitez, P., Goldstein, N. S., & Martinez, A. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg023 · Cited by 280
Osborne, C. K., Boldt, D. H., Clark, G. M., & Trent, J. M. (1983) · PubMed · Cited by 278
Cited by
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., Vega-Villegas, M. E., Eng, C., Steinhauer, E. U., Prausova, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1193 · Cited by 946
Scappaticci, F. A., Skillings, J. R., Holden, S. N., Gerber, H.-P., Miller, K., Kabbinavar, F., Bergsland, E., Ngai, J., Holmgren, E., Wang, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm086 · Cited by 938
Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E., & Sorosky, J. I. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5345 · Cited by 882
Gatzemeier, U., Pluzanska, A., Szczesna, A., Kaukel, E., Roubec, J., De Rosa, F., Milanowski, J., Karnicka-Mlodkowski, H., Pesek, M., Serwatowski, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1474 · Cited by 881
Metadata
- Authors
- Whelan, T., & Levine, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-01-01
- Volume
- 23
- Issue
- 1
- Pages
- 1-4
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2101020979
- Cited by
- 304
- References
- 15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Radiation Therapy and Tamoxifen: Concurrent or Sequential? That Is the Question. https://app.cochat.ai/papers/10.1200/jco.2005.08.955
- The paper
- Whelan, T., & Levine, M. (2005). Radiation Therapy and Tamoxifen: Concurrent or Sequential? That Is the Question. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.08.955
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.